207 related articles for article (PubMed ID: 37178730)
1. Clinical aspects and management of chronic itch.
Zeidler C; Raap U; Witte F; Ständer S
J Allergy Clin Immunol; 2023 Jul; 152(1):1-10. PubMed ID: 37178730
[TBL] [Abstract][Full Text] [Related]
2. New therapies for controlling atopic itch.
Furue M; Kadono T
J Dermatol; 2015 Sep; 42(9):847-50. PubMed ID: 26332459
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
4. [Prurigo nodularis: its association with dermatoses and systemic disorders].
Mettang T; Vonend A; Raap U
Hautarzt; 2014 Aug; 65(8):697-703. PubMed ID: 25113328
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
Gael M; Adam T; Mariano-Bourin M; Bursztejn AC
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1541-1551. PubMed ID: 35569006
[TBL] [Abstract][Full Text] [Related]
6. Itch in Atopic Dermatitis.
Kido-Nakahara M; Furue M; Ulzii D; Nakahara T
Immunol Allergy Clin North Am; 2017 Feb; 37(1):113-122. PubMed ID: 27886901
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of pruritus.
Ständer S; Weisshaar E; Raap U
Expert Opin Emerg Drugs; 2015 Sep; 20(3):515-21. PubMed ID: 26027744
[TBL] [Abstract][Full Text] [Related]
8. IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.
Roh YS; Choi J; Sutaria N; Belzberg M; Kwatra MM; Kwatra SG
Drugs; 2021 Jun; 81(8):895-905. PubMed ID: 33881741
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
10. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
11. Chronic itch in African Americans: an unmet need.
Ingrasci G; El-Kashlan N; Alexis A; Yosipovitch G
Arch Dermatol Res; 2022 Jul; 314(5):405-415. PubMed ID: 34129098
[TBL] [Abstract][Full Text] [Related]
12. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.
Steinke S; Zeidler C; Riepe C; Bruland P; Soto-Rey I; Storck M; Augustin M; Bobko S; Garcovich S; Legat FJ; Lvov A; Misery L; Osada N; Reich A; Şavk E; Serra-Baldrich E; Streit M; Szepietowski JC; Weger W; Dugas M; Ständer S
J Am Acad Dermatol; 2018 Sep; 79(3):457-463.e5. PubMed ID: 30119869
[TBL] [Abstract][Full Text] [Related]
13. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S; Zeidler C; Ständer S
Am J Clin Dermatol; 2024 Jan; 25(1):15-33. PubMed ID: 37717255
[TBL] [Abstract][Full Text] [Related]
14. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
15. Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives.
Kahremany S; Hofmann L; Harari M; Gruzman A; Cohen G
Pharmacol Rep; 2021 Apr; 73(2):443-453. PubMed ID: 33460006
[TBL] [Abstract][Full Text] [Related]
16. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
17. Use of Isoquercetin in the Treatment of Prurigo Nodularis.
Pennesi CM; Neely J; Marks AG; Basak SA
J Drugs Dermatol; 2017 Nov; 16(11):1156-1158. PubMed ID: 29141065
[TBL] [Abstract][Full Text] [Related]
18. Pruritus in Dermatology: Part 2 - Diseases and Their Treatment.
Navarro-Triviño FJ
Actas Dermosifiliogr; 2023; 114(7):613-626. PubMed ID: 37003460
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
20. Prurigo nodularis: Pathogenesis and management.
Williams KA; Huang AH; Belzberg M; Kwatra SG
J Am Acad Dermatol; 2020 Dec; 83(6):1567-1575. PubMed ID: 32461078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
